Biomarker Kit for Metastatic Breast Cancer Prognosis and Uses Thereof

A method for determining a prognosis, a stratification and/or for monitoring of a metastatic breast cancer in a patient, comprising the steps of:

• obtaining a biological sample from said patient;
• obtaining a control sample;
• measuring a level or activity of at least two of obscurin, PI3K, E-cadherin, or N-cadherin biomarkers for the metastatic breast cancer in the biological sample;
• measuring a level or activity of the at least two biomarkers in the control sample;
• and
• comparing the level or activity of said at least two biomarkers in the biological sample with the level or activity of said at least two biomarkers in the control sample, wherein a significant difference in the level or activity of said at least two biomarkers in said biological sample compared to said control sample is indicative for the presence of the metastatic breast cancer in said patient.

A method for determining a prognosis, a stratification and/or for monitoring of a metastatic cancer in a patient, comprising the steps of:

• obtaining a biological sample from said patient;
• obtaining a control sample;
• measuring a level or activity of biomarkers obscurins, PI3K, E-cadherin, and N-cadherin in said biological sample and in said control sample;
• and
• comparing the level or activity of said biomarkers in said sample with the level or activity in the control, wherein a significant difference in the level or activity of said biomarkers in the biological sample compared to the control sample is indicative for the presence of the metastatic cancer in said patient.